retatrutide clinical trial information parkinson's Retatrutide, an experimental drug currently in Phase 3 clinical trials, is nicknamed retatrutide clinical trials safety The

A pivotal 2021 clinical study of more than 1,900 adults, known as the STEP 1 trial, laid the groundwork for the use of these drugs as a treatment for weight loss

After one month of treatment, this $99 test maps 14 metabolic pathways and 150+ genetic insights to optimize your personalized therapy and predict outcomes more accurately

Unlike fad diets or extreme workout plans, medical weight loss is personalized to your unique health needs

In 2024, an estimated 2.8M individuals were enrolled in more than one Medicaid and/or ACA exchange plan, resulting in at least $4.3B in duplicate payments, while nearly 8.0M exchange enrollees (37%) did not generate a medical claim during the year

The main concerns with GLP-1 agonist drugs include: GI side effects (nausea, diarrhea, vomiting, constipation, abdominal pain) High out-of-pocket cost for those who do not quality under insurance Risk of inadequate nutrition (reduced intake + insufficient nutrition counseling) Significant loss of muscle mass & bone density High discontinuation rates (with lost weight regained) Limited public & clinician knowledge on importance/implementation of nutrition and lifestyle changes Side Effects and Costs of GLP-1 Medications The use of GLP-1 drugs has been associated with numerous side effects, ranging from mild to severe

There are growing concerns that adopting GLP-1 as a lifestyle drug is not ideal for everyone